<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39361576</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Assessing the impact of COVID-19 on tuberculosis detection and treatment in healthcare facilities across Addis Ababa, Ethiopia: A comprehensive mixed-method, multi-center study.</ArticleTitle><Pagination><StartPage>e0311408</StartPage><MedlinePgn>e0311408</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0311408</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0311408</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ethiopia faces a significant burden of Tuberculosis (TB), being one of the high-burden countries, and the emergence of the Coronavirus Disease 2019 (COVID-19) has become a dominant health concern, particularly in resource-limited settings. The repercussions of COVID-19 on TB care are evident, leading to a surge in undiagnosed TB cases, challenges in medication adherence, and an escalation of drug resistance. Consequently, a thorough assessment of the impact of COVID-19 on TB care becomes imperative to devise a tailored program for managing TB amidst future pandemics, natural disasters, and conflict crises.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A mixed-methods study design was utilized, encompassing a randomly selected 10 health centers (HCs) and 3 hospitals among government owned 98 HCs and 5 hospitals in Addis Ababa, Ethiopia. All TB patients who were on follow-up during the study period were included. The study period was from March 4, 2020, to December 4, 2020, with the corresponding period of March 4, 2019, to December 4, 2019, serving as the baseline for comparison. Quantitative data were gathered from TB patients' medical registries, laboratory registries, and treatment follow-up charts. Complementary qualitative data were acquired through in-depth interviews. Both qualitative and quantitative data were collected from January 17, 2022 to May 13, 2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Following the onset of the pandemic, there was a notable and statistically significant decline in both the detection of TB cases and the number of positive results across all study sites. Bacteriological TB tests reduced from 5837 to 2126 patients, and TB-positive cases decreased from 500 to 218, representing declines of 63.6% and 56.4%, respectively. The overall number of TB patients undergoing treatment also experienced a decrease from 1431 to 1051, marking a 26.6% reduction. Additionally, there was a 10% increase in the proportion of extra-pulmonary TB cases. The impact of the pandemic extended to TB treatment outcomes, with adverse effects on cure rates, death rates, loss of follow-up, and medication adherence. The apprehension of contracting COVID-19 and the implementation of isolation measures contributed to a decline in healthcare-seeking behaviors among patients, fostering negative perceptions and practices among healthcare workers. The challenges further exacerbated due to a shortage of personal protective equipment, a lack of rapid diagnostic test tools, clinical presentations resembling COVID-19, and a shift in government policies. These factors collectively posed significant obstacles to effective TB care during the pandemic.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The profound impact of COVID-19 on critical TB care service indicators, including TB detection, treatment initiation, and treatment outcomes, underscores the need for immediate and collaborative measures. It is imperative to implement strategies that ensure the resumption of all TB care services concurrently with efforts to control COVID-19. A comprehensive and coordinated approach is essential to mitigate the adverse effects of the pandemic on TB management and safeguard public health.</AbstractText><CopyrightInformation>Copyright: Â© 2024 Nasir et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nasir</LastName><ForeName>Beshir Bedru</ForeName><Initials>BB</Initials><Identifier Source="ORCID">0000-0002-8246-9640</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammed</LastName><ForeName>Oumer Sada</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamiru</LastName><ForeName>Melaku Tileku</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chelkeba</LastName><ForeName>Legese</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005002" MajorTopicYN="N" Type="Geographic">Ethiopia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006268" MajorTopicYN="Y">Health Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39361576</ArticleId><ArticleId IdType="pmc">PMC11449274</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0311408</ArticleId><ArticleId IdType="pii">PONE-D-24-05553</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mohammed H, Oljira L, Roba KT, Yimer G, Fekadu A, Manyazewal T. Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research. Infectious Diseases of Poverty. 2020. Dec;9(1):1â8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492795</ArticleId><ArticleId IdType="pubmed">32938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Alene KA, Wangdi K, Clements AC. Impact of the COVID-19 pandemic on tuberculosis control: an overview. Tropical Medicine and Infectious Disease. 2020. Sep;5(3):123. doi: 10.3390/tropicalmed5030123</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed5030123</ArticleId><ArticleId IdType="pmc">PMC7558533</ArticleId><ArticleId IdType="pubmed">32722014</ArticleId></ArticleIdList></Reference><Reference><Citation>Global tuberculosis report World Health Organization. 2018</Citation></Reference><Reference><Citation>Federal Democratic Republic of Ethiopia.National treatment guideline for TB, DRTB and leprosy. 2017</Citation></Reference><Reference><Citation>Khan MS, Rego S, Rajal JB, Bond V, Fatima RK, Isani AK, et al.. Mitigating the impact of COVID-19 on tuberculosis and HIV services: a cross-sectional survey of 669 health professionals in 64 low and middle-income countries. PloS one. 2021. Feb 2;16(2):e0244936. doi: 10.1371/journal.pone.0244936</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244936</ArticleId><ArticleId IdType="pmc">PMC7853462</ArticleId><ArticleId IdType="pubmed">33529206</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei H, Yinyin X, Hui C, Ni W, Xin D, Wei C, et al.. The impact of the COVID-19 epidemic on tuberculosis control in China. The Lancet Regional Health-Western Pacific. 2020. Oct 1;3:100032. doi: 10.1016/j.lanwpc.2020.100032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2020.100032</ArticleId><ArticleId IdType="pmc">PMC7511841</ArticleId><ArticleId IdType="pubmed">34173601</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro P, Formenti B, Marchese V, Gulletta M, Tomasoni LR, Caligaris S, et al.. Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy. European Respiratory Journal. 2020. Oct 1;56(4). doi: 10.1183/13993003.02665-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02665-2020</ArticleId><ArticleId IdType="pmc">PMC7377210</ArticleId><ArticleId IdType="pubmed">32703780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbithi I, Thekkur P, Chakaya JM, Onyango E, Owiti P, Njeri NC, et al.. Assessing the Real-Time Impact of COVID-19 on TB and HIV Services: The Experience and Response from Selected Health Facilities in Nairobi, Kenya. Tropical Medicine and Infectious Disease. 2021;6(2):74. doi: 10.3390/tropicalmed6020074</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed6020074</ArticleId><ArticleId IdType="pmc">PMC8163186</ArticleId><ArticleId IdType="pubmed">34068615</ArticleId></ArticleIdList></Reference><Reference><Citation>Adewole OO. Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria. Int J Tuberc Lung Dis. 2020. Sep 1;24(9):981â2. doi: 10.5588/ijtld.20.0418</Citation><ArticleIdList><ArticleId IdType="doi">10.5588/ijtld.20.0418</ArticleId><ArticleId IdType="pubmed">33156771</ArticleId></ArticleIdList></Reference><Reference><Citation>Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Annals of clinical microbiology and antimicrobials. 2020. Dec;19:1â6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245173</ArticleId><ArticleId IdType="pubmed">32446305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakoh S, Jiba DF, Baldeh M, Adekanmbi O, Barrie U, Seisay AL, et al.. Impact of COVID-19 on tuberculosis case detection and treatment outcomes in Sierra Leone. Tropical Medicine and Infectious Disease. 2021. Aug 19;6(3):154. doi: 10.3390/tropicalmed6030154</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed6030154</ArticleId><ArticleId IdType="pmc">PMC8396336</ArticleId><ArticleId IdType="pubmed">34449755</ArticleId></ArticleIdList></Reference><Reference><Citation>World health Organization. Impact of covid-19 on TB detection and mortality. 2022.available at https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020</Citation></Reference><Reference><Citation>Kadota JL, Reza TF, Nalugwa T, et al.. Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic. Int J Tuberc Lung Dis 2020;24:1212â4. doi: 10.5588/ijtld.20.0626</Citation><ArticleIdList><ArticleId IdType="doi">10.5588/ijtld.20.0626</ArticleId><ArticleId IdType="pmc">PMC7895296</ArticleId><ArticleId IdType="pubmed">33172531</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Communicable Diseases. Impact of COVID-19 intervention on TB testing in South Africa 2020.</Citation></Reference><Reference><Citation>Youn S. Korea TB treatment success rate falls temporarily after Covid-19. Korea Biomed review 2020;11:44.</Citation></Reference><Reference><Citation>Moonan P.K., Quitugua T.N., Pogoda J.M., Woo G., Drewyer G., Sahbazian B., et al.. 2011. Does directly observed therapy (DOT) reduce drug resistant tuberculosis?. BMC public health, 11, pp.1â8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032680</ArticleId><ArticleId IdType="pubmed">21214913</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, Isaakidis P, Armstrong E, Gundipudi NR, Babu RB, Qureshi IA, et al.. Directly-observed and self-administered tuberculosis treatment in a chronic, low-intensity conflict setting in India. PLoS One. 2014. Mar 20;9(3):e92131. doi: 10.1371/journal.pone.0092131</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092131</ArticleId><ArticleId IdType="pmc">PMC3961301</ArticleId><ArticleId IdType="pubmed">24651176</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi S, Tahir M. Effectiveness of directly observed therapy short course (dots) in patients with tuberculosis registered at federal general hospital, Islamabad. International Journal of Infectious Diseases. 2018. Aug 1;73:344.</Citation></Reference><Reference><Citation>Silva BP, Almeida AS, SÃ©rgio MG, Gatto TC, Carasek VP, Yamamura M. Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance. Revista Brasileira de Enfermagem. 2023. Dec 4;76(Suppl 1):e20220803. doi: 10.1590/0034-7167-2022-0803</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0034-7167-2022-0803</ArticleId><ArticleId IdType="pmc">PMC10695069</ArticleId><ArticleId IdType="pubmed">38055430</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>